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Purpose: To report the patient characteristics and treatment outcomes in 12 cases of orbital lymphangioma.
Methods: In this study, orbital lymphangioma was diagnosed based on clinical, radiologic (computed tomog-
raphy, magnetic resonance imaging), and histologic findings when possible. Patients whose vision was not 
compromised by orbital lymphangioma, or that did not have increased intraocular pressure (IOP), received 
oral corticosteroids. Orbital lymphangioma that affected vision or increased IOP was treated by surgery, which 
included aspiration of blood or partial resection with or without injection of a sclerosant.
Results: Four patients without compromised vision responded well to oral corticosteroids. Eight patients with 
compromised vision underwent some form of surgery. Bleeding recurred in three patients after aspiration of 
blood and in two after partial resection and intralesional injection of a sclerosant. Overall, five patients were 
treated successfully by aspiration of blood, intralesional injection of a sclerosant, and application of continuous 
negative pressure by appropriate drainage. Partial resection was successful in two patients with organized he-
matoma.
Conclusions: Orbital lymphangioma that does not compromise vision can be treated medically using oral corti-
costeroids. Patients with threatened vision or elevated IOP due to acute hemorrhage should be treated by as-
piration of blood, intralesional injection of a sclerosant, and application of continuous negative pressure. Partial 
resection may be effective only in patients with organized hematoma.
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Lymphangioma is a benign tumor of the lymphatic sys- tem that is characterized by abnormal endothelial-lined 
channels [1]. Generally found in the head and neck region, 
these tumors constitute 0.3% to 4% of all orbital tumors 
and are not considered hamartomas because the orbit does 
not usually contain lymphatic vessels [2,3]. Some patients 
with orbital lymphangioma may develop proptosis, either 
slowly as the mass invades the orbit or suddenly during 
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hemorrhage of a lesion [3]. In childhood, the diagnosis is 
often made when proptosis occurs after bleeding as a re-
sult of minor trauma or upper respiratory infection, and 
may even occur spontaneously. The lymphangioma itself 
or the associated bleeding can restrict ocular motility and 
cause compressive optic neuropathy because of its mass [4].
Lymphangiomas can also infiltrate diffusely into sur-
rounding vital structures such as the optic nerve. This char-
acteristic, along with the associated hemorrhage, presents 
many surgical challenges and renders management of orbit-
al lymphangiomas very difficult. Several methods have been 
used to treat orbital lymphangioma, including systemic cor-
ticosteroids, injection of a sclerosant, and surgical excision, 
but currently, there are no definitive curative treatments [5,6]. 
Case reports and studies of orbital lymphangioma are rare in 
the Korean population. Here we describe the characteristics 
and treatment outcomes in 12 Korean patients with orbital 
lymphangioma.
Materials and Methods
We retrospectively reviewed the medical records of 12 
patients that had been diagnosed with orbital lymphangio-
ma between January 2005 and May 2015 at the Severance 
Hospital, Yonsei University College of Medicine, Seoul, Ko-
rea. The diagnosis was based on clinical manifestations, 
imaging studies, including computed tomography and mag-
netic resonance imaging (MRI), and histologic findings 
when possible. Ophthalmic evaluation included measure-
ment of visual acuity, intraocular pressure (IOP), ocular 
motility, and Hertel exophthalmometry. Patients without 
elevated IOP and no immediate threat to vision were treat-
ed with oral corticosteroids. Patients threatened with loss 
of vision or severe disfigurement underwent aspiration of 
blood or partial resection (with or without intralesional in-
jection of a sclerosant and application of continuous nega-
tive pressure). The study adhered to the tenets of the Dec-
laration of Helsinki. Ethical approval to conduct the study 
was obtained from the institutional review board at the Sev-
erance Hospital of Yonsei University (No. 4-2015-0342).
Results
The demographic and clinical characteristics of the pa-
tients are detailed in Table 1. The mean patient age at pre-
sentation was 14.7 years (range, 1 to 76; median, 5.5). Seven 
patients were male and five were female. Ten patients were 
diagnosed with orbital lymphangioma in childhood. The 
mean follow-up period was 22.8 months (range, 2 to 68). 
All of the patients initially presented with proptosis due to 
lesional hemorrhage and mass effect of the tumor. The 
causes of bleeding included blunt ocular trauma (n = 3), 
upper respiratory infection (n = 2), and a spontaneous 
event (n = 7). The tumors were classified as superficial (n = 
0), deep (n = 6), combined (n = 4), or complex (n = 2) [5].
In patients that could be tested for visual acuity (n = 10), 
all but one had a visual acuity at presentation above 20 / 
50. One patient had a visual acuity of 10 / 200 and two pa-
tients could not be tested because of their young age. 
During treatment, one patient showed worsening of visual 
acuity to light perception negative, but the other patients 
did not experience any further impairment of visual acui-
ty. An IOP above 21 mmHg was recorded in four patients. 
All patients had limited ocular motility and three had 
compressive optic neuropathy before or during follow-up. 
Four patients (cases 6, 8, 11, and 12) were treated with 
oral corticosteroids only (Fig. 1A and 1B), but eight re-
quired some form of surgical intervention. Five of the eight 
surgically treated patients experienced a recurrence of one 
or more hemorrhagic episodes. Among these, two patients 
(cases 4 and 7) underwent a partial resection and received 
an intralesional injection of a sclerosant, and three patients 
(cases 1, 5, and 10) underwent aspiration of blood (Fig. 2). 
In the two patients who underwent partial resection (cases 
4 and 7), bleeding recurred from posterior residual lymph-
angioma tissue. At reoperation, this residual tissue was 
difficult to approach due to its deep location. Overall, five 
patients (cases 1, 2, 3, 4, and 7) were treated successfully 
by aspiration of blood, intralesional injection of a sclero-
sant (OK-432 in two cases and bleomycin in three cases), 
and application of continuous negative pressure by appro-
priate drainage. Two patients (cases 9 and 10) experienced 
organized hematoma that caused proptosis for several 
months, but after partial resection, these patients eventual-
ly had favorable outcomes (Table 1).
Case 4 description
 A 4-year-old girl presented with a 1-day history of 
left-sided proptosis and eyelid swelling (Fig. 3A). She had 
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been treated with OK-432 (Picibanil; Chugai Pharmaceuti-
cal, Tokyo, Japan) for a lymphatic malformation on her left 
forehead, frontal and temporal scalp 3 years previously, 
and the lesions had shrunk and little remained. Visual acu-
ity in her affected eye was 20 / 30 and the IOP was 20 
mmHg. Ocular motility was restricted in all directions and 
the degree of proptosis was 13 mm on the right and 19 mm 
on the left. MRI confirmed a diagnosis of lymphangioma, 
which consisted of multiple diffusely infiltrating cysts 
with fluid-fluid levels (Fig. 3B and 3C). The following day, 
the lesion was approached with a left upper eyelid sub-
brow incision (Fig. 3D). Blood was aspirated, the lymphan-
gioma was partially resected (Fig. 3E), and 0.05 mg of OK-
432 diluted in 1 mL of physiologic saline was injected into 
the deep residual mass. The size of the mass subsequently 
decreased, which relieved the proptosis (Fig. 3F).
Thirty months later, the patient presented again after de-
veloping severe painful proptosis and eyelid swelling, with 
vision that had decreased to 20 / 200 (Fig. 3G). A grade 2 
relative afferent pupillary block was noted in her left eye. 
MRI showed recurrence of bleeding from the residual lymph-
angioma tissue (Fig. 3H). Blood was aspirated via the pre-
vious incision site and bleomycin (1 IU per mL of saline) 
was injected intralesionally over 10 minutes. A drain was 
inserted but did not function well. Bleeding recurred on 
the following day and the patient’s proptosis worsened. 
The previous incision site was reopened; blood was evacu-
ated with a suction catheter; and the same concentration of 
bleomycin was injected into the residual mass over 10 min-
utes. Another drain was inserted and continuous negative 
pressure was applied, with marked resolution of the pro-
ptosis. Oral corticosteroids (10 mg/day) were given for 2 
weeks and then tapered. The final visual acuity in the af-
fected eye was light perception negative, most likely due to 
compression of the optic nerve by intraorbital hemorrhage. 
The hemorrhage around the optic nerve was evacuated 
carefully, so it is unlikely that damage to the optic nerve 
was caused by the surgery itself. The proptosis normalized 
2 months after reoperation (Fig. 3I), and no additional 
hemorrhagic episodes have occurred in 12 months of fol-
low-up observation.
Case 7 description
A 1-year-old boy presented with a 1-month history of 
right proptosis. He had previously been diagnosed with 
cystic lymphangioma on the right forehead. The forehead 
lesion had been surgically excised 7 months after birth, 
and remained small in size. MRI showed non-encapsulated 
lobulated intraconal and extraconal cystic masses in the 
right orbit. These were treated by aspiration of 5 mL of 
blood, partial resection of the mass, and an injection of 
OK-432 0.05 mg in 5 mL of physiologic saline into the an-
terior orbitotomy site over 5 minutes. Two days later, the 
patient’s proptosis worsened because of hemorrhage, so 12 
mL of blood was aspirated through the previous opening 
site and drainage material was inserted. Then, 10 mg of 
prednisolone was started on a tapering schedule, and the 
proptosis decreased. Four months after surgery, proptosis 
recurred in the right eye. MRI revealed a hemorrhage be-
hind the previous lesion, so 12.5 mg of oral corticosteroids 
were administered and the proptosis slowly subsided. Six 
A
B
Fig. 1. Patients with orbital lymphangioma that were successfully 
treated with oral corticosteroids. (A) Case 6, (B) case 8 (left col-
umn, pretreatment; right column, posttreatment).
Fig. 2. Treatment modalities of patients with orbital lymphangio-
ma who underwent surgical intervention and experienced recur-
rent hemorrhage.
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months later, severe eyelid swelling and proptosis were ob-
served. MRI showed an increase in size of the lymphangi-
oma and hemorrhage in the right orbit. Blood was aspirat-
ed from the mass lesion and a sclerosant (bleomycin, 1 IU 
per mL of saline) was injected into the cyst over 5 minutes. 
Drainage material was then inserted to create negative 
pressure inside the lesion. After surgery, oral corticoste-
roids and sildenafil (3.3 mg/day) were started. The sildena-
fil was not associated with any adverse reactions and no 
additional hemorrhagic episodes have occurred during 6 
months of follow-up.
Case 10 description
A 19-year-old man was referred to our clinic with left-sid-
ed proptosis and eyelid swelling. He had been diagnosed 
with orbital lymphangioma 16 years previously. Visual 
acuity in the left eye was 20 / 30; IOP was 16 mmHg; mo-
tility was restricted; and the degree of proptosis was 20 
mm (13 mm on the right). MRI findings were consistent 
with orbital lymphangioma. At the time of the initial diag-
nosis, the patient had good visual acuity and IOP in the 
normal range, so he initially declined treatment. Three 
years later, severe proptosis (28 mm on exopthalmometry) 
developed in his left eye following an upper respiratory in-
fection which required intervention, and 5 mL of blood 
was aspirated and oral corticosteroid therapy (40 mg/day) 
was started on a tapering schedule. His symptoms seemed 
to improve for 6 weeks, but then worsened. The degree of 
left-sided proptosis increased to 35 mm (Fig. 4A and 4B), 
and MRI showed large diffuse cysts with an organized he-
matoma in the left orbit (Fig. 4C and 4D). After discussion 
with a radiologist, the affected orbit was irradiated with 20 
Gy; however, this did not improve his proptosis or con-
junctival edema. Sildenafil, at a dose of 25 mg/day, was 
started in an attempt to reduce the lesion size [7]. The mass 
was then carefully resected via a lateral orbitotomy and a 
drain was inserted into the remaining lesion. After surgery, 
A B C
D E F
G H I
Fig. 3. Four-year-old girl with left orbital lymphangioma. (A) Proptosis at initial visit. (B) Axial T2-weighted magnetic resonance image 
showing multiple diffusely-infiltrating cysts. (C) Coronal T2-weighted magnetic resonance image showing cysts with fluid-fluid levels. 
(D) Lymphangioma observed via the anterior orbitotomy site. (E) Partially-resected lymphangioma. (F) Axial T2-weighted magnetic res-
onance image showing that the cystic mass had been removed from the left orbit. (G) Bleeding recurred 30 months after the first surgical 
intervention. (H) Axial T2-weighted magnetic resonance image indicating bleeding from deep residual lymphangiomatous tissue. (I) Ap-
pearance 6 months after the repeated surgery; bleeding has not recurred, but the patient's visual acuity has changed to no light perception. 
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the degree of proptosis was reduced to 16 mm and visual 
acuity was unimpaired, although hypotropia developed, 
along with ocular motility limitations (Fig. 4E and 4F). 
During 8 months of follow-up, hemorrhagic episodes have 
not recurred in this patient.
Discussion
Orbital lymphangioma is often detected when intrale-
sional hemorrhage induces proptosis, which can occur ei-
ther suddenly or gradually. Compressive optic neuropathy 
can develop when the hemorrhage is massive or the tumor 
itself compresses the optic nerve. Tunc et al. [8] reported 
that 85% of their patients with orbital lymphangioma had 
proptosis; 73% had ptosis; and 46% had reduced ocular 
motility. In our case series, all 12 patients had proptosis 
and limited ocular motility at presentation. Two patients 
had compressive optic neuropathy at presentation and one 
patient had visual acuity that deteriorated to light percep-
tion negative, most likely because of prolonged compres-
sion of the optic nerve by intraorbital hemorrhage.
Orbital lymphangioma can be classified into four types 
based on location [5,9]. The superficial type is character-
ized by subcutaneous or conjunctival lesions; the deep 
type shows orbital invasion; the combined type has super-
ficial and deep components; and the complex type involves 
other head and neck structures. The tumors in our study 
were classified as deep, combined, and complex in six, 
four, and two patients, respectively. The mean age of our 
patients at presentation was 14.7 years, and 10 were diag-
nosed with orbital lymphangioma in childhood. Because of 
the frequent early onset, treatment for orbital lymphangio-
ma is directed at preventing amblyopia and preserving vi-
sual acuity [5].
On computed tomography, orbital lymphangioma appears 
as a mildly enhancing cystic mass. MRI usually shows find-
ings similar to those of computed tomography, but has bet-
ter diagnostic accuracy because of higher resolution, and is 
safer because of the lack of ionizing radiation [10,11]. MRI 
may also indicate the presence of feeder vessels, in which 
case a diagnosis of orbital lymphangioma is excluded [12-
14]. Overall, radiologic analysis alone has a diagnostic 
specificity of 77% for this type of tumor. However, orbital 
lymphangioma can sometimes be misdiagnosed as orbital 
hemangioma, rhabdomyosarcoma, or lymphoma when 
only imaging studies are used [7]. For this reason, in addi-
tion to diagnosing the tumor based on clinical and radio-
logic findings, we also confirmed the diagnosis histologi-
cally when a surgical intervention was performed.
Diffuse infiltration and associated hemorrhage make this 
type of tumor difficult to remove surgically. Oral cortico-
steroid therapy alone was effective in four of our patients, 
which is consistent with previous reports [14,15]. Systemic 
corticosteroids reduce lymphoid hypertrophy and stabilize 
the abnormal vasculature, leading to resolution of the 
lymphangioma. Therefore, orbital lymphangiomas do not 
necessarily require surgical intervention unless there are 
vision-threatening or severely disfiguring lesions [15,16].
Another useful modality for treating lymphangioma is 
intralesional injection of a sclerosant such as OK-432 or 
bleomycin [3,5,17]. OK-432 is prepared from a low-viru-
lence Su strain of group A Streptococcus pyogenes of hu-
man origin treated with penicillin G. It has been used to 
treat malignant tumors, pleural effusion, and malignant 
ascites [18,19]. According to Giguere et al. [20], injection of 
OK-432 decreases the size of head and neck lymphangio-
mas. This claim is supported by case reports which demon-
strated that orbital lymphangiomas are treatable with in-
A B
C D
E F
Fig. 4. Nineteen-year-old man with a 16-year history of left 
orbital lymphangioma. (A) Severe proptosis and conjunctival 
swelling before resection. (B) Exophthalmometry showing 35-mm 
protrusion of the left eyeball. (C) Coronal T2-weighted magnetic 
resonance image showing lymphangioma that occupied most of 
the left orbit. (D) Axial T2-weighted magnetic resonance image 
showing a large lymphangioma with organized hematoma an-
teriorly displacing the left eyeball. (E) Reduced proptosis after 
partial resection. (F) Computed tomography image after partial 
resection.
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tralesional OK-432 [21,22]. Bleomycin, first isolated from 
Streptomyces verticillus in 1966 [23], has a sclerosing ef-
fect on vascular endothelial cells and has been used to treat 
pleural effusion and vascular anomalies [24]. A literature 
search revealed that there were a few reports on the use of 
bleomycin injections to treat orbital lymphangioma, with 
no systemic or ophthalmic complications [4,25]. In our 
case series, five patients were successfully treated with in-
tralesional injections of a sclerosant and application of 
continuous negative pressure. However, hemorrhage re-
curred in patients who received injection of a sclerosant 
without application of continuous negative pressure. Thus, 
it is recommended that this modality be combined with as-
piration of blood and application of continuous negative 
pressure using a correctly positioned drain.
Two patients received oral sildenafil in our study. Silde-
nafil causes cystic lesions to collapse by decreasing the 
contractility of vascular smooth muscle [7,26]. However, 
we did not confirm this effect in our patients. The most com-
mon adverse reactions of sildenafil are pyrexia, gastroin-
testinal discomfort, cough, sleep disturbance, and migraine, 
but these were not observed in our cases. In one patient, 
orbital lymphangioma was fractionally irradiated with 20 
Gy, as recommended by Portnow et al. [27], with the goal 
of reducing the size of the lesion. However, lymphangioma 
is not a rapidly proliferating lesion, so radiotherapy was 
ineffective for this purpose.
Five patients in our case series experienced recurrent 
hemorrhage. Two patients that had undergone partial re-
section and intralesional injection of a sclerosant during an 
acute hemorrhagic episode experienced recurrence of 
hemorrhage from the remaining lymphangioma tissue sev-
eral months after treatment. The posterior location of the 
residual mass made it difficult to evacuate blood and inject 
the sclerosant in these patients. Therefore, these findings 
indicate that the surgical approach becomes more difficult 
when bleeding occurs after partial resection. MRI showed 
that the mass tended to bulge toward the retrobulbar in-
traconal space, because adhesions that arose after previous 
surgery blocked any superficial expansion. We hypothesize 
that a decrease in the available expansion space could in-
crease the risk of compressive optic neuropathy. Three pa-
tients who only underwent aspiration of blood also experi-
enced recurrent hemorrhage, but blood could be easily 
removed through the previous incision site. In comparison, 
the patients in this study had favorable outcomes when 
partial resection was applied, as demonstrated by the two 
cases of orbital lymphangioma that were associated with 
organized hematoma.
In summary, orbital lymphangioma that is not threaten-
ing to vision can be medically treated with oral corticoste-
roids. We suggest that aspiration of blood, intralesional in-
jection of a sclerosant, and appropriate drainage to maintain 
continuous negative pressure are only necessary for pa-
tients that have threatened vision, as we reported previous-
ly [4]. Additionally, in cases of orbital lymphangioma that 
are associated with organized hematoma, partial resection 
can be considered to debulk the mass.
This case series describes manifestations and treatment 
outcomes of orbital lymphangioma in the Korean popula-
tion. Our report helps to further knowledge on the clinical 
course, prognosis, and appropriate treatment modalities for 
patients with orbital lymphangioma.
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